GSK Q1 Strength Signals Tariff Resilience

British pharma heavyweight GSK reports a strong start to 2025 with earnings exceeding forecasts and reaffirms its growth outlook—positioning itself as a stable force even as potential U.S. pharmaceutical tariffs loom.

Why the Federal Reserve Is Holding Off on Interest Rate Cuts

While other central banks begin easing policy in response to slowing global growth, the Federal Reserve is holding firm. Concerns about inflation, unemployment, and the uncertain impact of U.S. trade policy are keeping rate cuts off the table – for now.

Should Investors Rush to Gold EFTs?

As economic uncertainty, inflation fears, and trade tensions shake investor confidence, Gold ETFs are emerging as a reliable hedge and a strategic portfolio enhancer. Learn why now may be the right time to lean into gold.

Hyundai’s $21 Billion U.S. Investment: A Strategic Move in a Shifting Market

Hyundai Motor Group is committing $21 billion to expand its presence in the United States. This investment focuses on growing manufacturing capacity, strengthening supply chains, and adapting to changing trade policies. With new tariffs and evolving regulations shaping the industry, Hyundai’s expansion aligns with broader trends favoring domestic production.

The Quantum Revolution is Here

Quantum computing is on the verge of transforming industries, offering unprecedented computational power that could redefine fields ranging from materials science to AI

Invested in Chip Stocks? Note this Mineral Ban

China’s export restrictions on gallium and germanium are shaking up global supply chains. As industries adapt, investors are closely watching the U.S. for opportunities in domestic suppliers with strong growth potential.

Novartis Bets Big on Cardiovascular Biotech With $3bn Anthos Deal

Swiss pharmaceutical giant Novartis has announced an agreement to acquire Anthos Therapeutics from Blackstone Life Sciences in a deal valued at up to $3.1 Billion. The deal includes a $925 Million upfront payment, with additional payouts tied to future regulatory and commercial success. Investment Implications For Novartis: This move allows Novartis to regain abelacimab, a […]

de_DEGerman